Bicycle Therapeutics
BCYC | NASDAQ
$3.18
-$0.19 (-5.64%)
At close: Nov 16, 2026, 4:00 PM ET
$3.22
+$0.04 (+1.26%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.64%
(1D)No price chart data available for 1D timeframe.
Rating
42.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #450/1021 (Top 44%)
Key Statistics
Market Data
Market Cap $222.58M
1D Range
3.07 3.36
52W Range
3.07 7.52
Valuation (TTM)
PE -1.57
PB 0.44
EV/EBITDA 1.74
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $10.00
Cash Flow
FCF Yield -79.4%
SBC Adj. FCF Yield -75.3%
SBC Impact -5.1%
Margins
Gross Margin 100.0%
Operating Margin -189.5%
FCF Margin -211.6%
Growth (CAGR)
Revenue 3Y | 5Y 49.8% |
48.0%
Dil EPS 3Y | 5Y 21.2% |
12.0%
FCF 3Y | 5Y 6.5% |
-25.4%
Returns
ROA -25.0%
ROE -26.0%
ROIC -30.2%
Financial Health
Net Cash
$469.93M
Current Ratio 12.09
Interest Coverage -815.89
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently...
Sector Healthcare
Industry Biotechnology
Employees 288
IPO Date May 23, 2019
Website www.bicycletherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Oct 29, 2026
EPS
-$0.15
Beat +50.00%
YoY:
+82.35% REV
$34.06M
Beat +178.74%
YoY:
+190.24%Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$10.00
Upside
+214.47%
Buy (3)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove BCYC